Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

MicroRNA-497 impairs the growth of chemoresistant neuroblastoma cells by targeting cell cycle, survival and vascular permeability genes

  • Soriano, Aroa|||0000-0001-9659-1471
  • París-Coderch, Laia|||0000-0003-2145-5752
  • Jubierre Zapater, Luz
  • Martínez, Alba
  • Zhou, Xiangyu
  • Piskareva, Olga
  • Bray, Isabella
  • Vidal, Isaac
  • Almazán-Moga, Anna
  • Molist, Carla|||0000-0003-3251-0083
  • Roma, Josep|||0000-0001-7692-6123
  • Bayascas Ramírez, José Ramón|||0000-0002-6096-2151
  • Casanovas, Oriol|||0000-0002-4298-3995
  • Stallings, Raymond L.
  • Sánchez de Toledo Codina, José|||0000-0002-1034-1920
  • Gallego, Soledad|||0000-0002-4712-9624
  • Segura, Miguel F.|||0000-0003-0916-3618
Despite multimodal therapies, a high percentage of high-risk neuroblastoma (NB) become refractory to current treatments, most of which interfere with cell cycle and DNA synthesis or function, activating the DNA damage response (DDR). In cancer, this process is frequently altered by deregulated expression or function of several genes which contribute to multidrug resistance (MDR). MicroRNAs are outstanding candidates for therapy since a single microRNA can modulate the expression of multiple genes of the same or different pathways, thus hindering the development of resistance mechanisms by the tumor. We found several genes implicated in the MDR to be overexpressed in high-risk NB which could be targeted by microRNAs simultaneously. Our functional screening identified several of those microRNAs that reduced proliferation of chemoresistant NB cell lines, the best of which was miR-497. Low expression of miR-497 correlated with poor patient outcome. The overexpression of miR-497 reduced the proliferation of multiple chemoresistant NB cell lines and induced apoptosis in MYCN-amplified cell lines. Moreover, the conditional expression of miR-497 in NB xenografts reduced tumor growth and inhibited vascular permeabilization. MiR-497 targets multiple genes related to the DDR, cell cycle, survival and angiogenesis, which renders this molecule a promising candidate for NB therapy.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Functional high-throughput screening reveals miR-323a-5p and miR-342-5p as new tumor-suppressive microRNA for neuroblastoma

  • Soriano, Aroa|||0000-0001-9659-1471
  • Masanas, Marc|||0000-0002-2249-8554
  • Boloix, Ariadna|||0000-0002-1648-5589
  • Masiá, Núria
  • París-Coderch, Laia|||0000-0003-2145-5752
  • Piskareva, Olga
  • Jiménez Jiménez, Carlos|||0000-0001-9219-3492
  • Henrich, Kai-Oliver
  • Roma, Josep|||0000-0001-7692-6123
  • Westermann, Frank
  • Stallings, Raymond L.
  • Sábado, Constantino|||0000-0003-3956-5466
  • Sánchez de Toledo Codina, José|||0000-0002-1034-1920
  • Santamaría Margalef, Anna|||0000-0001-6726-8990
  • Gallego, Soledad|||0000-0002-4712-9624
  • Segura, Miguel F.|||0000-0003-0916-3618
The online version of this article (10.1007/s00018-019-03041-4) contains supplementary material, which is available to authorized users., Current therapies for most non-infectious diseases are directed at or affect functionality of the human translated genome, barely 2% of all genetic information. By contrast, the therapeutic potential of targeting the transcriptome, ~ 70% of the genome, remains largely unexplored. RNA therapeutics is an emerging field that widens the range of druggable targets and includes elements such as microRNA. Here, we sought to screen for microRNA with tumor-suppressive functions in neuro-blastoma, an aggressive pediatric tumor of the sympathetic nervous system that requires the development of new therapies. We found miR-323a-5p and miR-342-5p to be capable of reducing cell proliferation in multiple neuroblastoma cell lines in vitro and in vivo, thereby providing a proof of concept for miRNA-based therapies for neuroblastoma. Furthermore, the combined inhibition of the direct identified targets such as CCND1, CHAF1A, INCENP and BCL-XL could reveal new vulnerabilities of high-risk neuroblastoma.